肝动脉及部分脾动脉栓塞治疗肝癌伴脾功能亢进

目的：临床采用肝动脉栓塞化疗联合部分脾动脉栓治疗原发性肝癌合并脾功能亢进的效。方法：住院原了肝癌伴肝硬化脾功能亢进患者３４例,采用经皮穿刺肝动脉插管化疗栓塞及脾动脉部分栓塞治疗。治疗前后行检测肝功能、指标、外周血及Ｂ超、ＣＴ等。结果：术后ＣＴ随访显示肝脏瘤体缩小２４例,占７０．５８％（２４／３４）,其中缩小５０％以上者１３例,２例治疗后肝功能行二期抹切除;脾脏栓塞后ＣＴ复查缩小,最多３４．７％,最     

部分脾栓塞术联合TACE治疗原发性肝癌伴脾功能亢进的研究进展

脾功能亢进是原发性肝癌肝硬化门静脉高压的严重并发症之一,部分脾栓塞术（PSE）在治疗脾功能亢进上具有安全、有效、可重复、微创且能保留脾脏部分免疫功能等优点,已在经导管肝动脉化疗栓塞术（TACE）治疗原发性肝癌伴脾功能亢进中具有举足轻重的作用。本文主要对原发性肝癌发生脾功能亢进的机制、PSE的优势、操作方法及术后常见并发症进行综述。     

Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism:A casecontrol study

AIM:To investigate whether the use of synchronoushepatectomy and splenectomy(HS)is more effective than hepatectomy alone(HA)for patients with hepatocellular carcinoma(HCC)and hypersplenism.METHODS:From January 2007 to March 2013,84consecutive patients with HCC and hypersplenism who underwent synchronous hepatectomy and splenectomy in our center were compared with 84 well-matched patients from a pool of 268 patients who underwent hepatectomy alone.The short-term and longterm outcomes of the two groups were analyzed and compared.RESULTS:The mean time to recurrence was 21.11±12.04 mo in the HS group and 11.23±8.73 mo in the HA group,and these values were significantly different(P=0.001).The 1-,3-,5-,and 7-year disease-free survival rates for the patients in the HS group and the HA group were 86.7%,70.9%,52.7%,and 45.9%and 88.1%,59.4%,43.3%,and 39.5%,respectively(P=0.008).Platelet and white blood cell counts in the HS group were significantly increased compared with the HA group one day,one week,one month and one year postoperatively(P0.001).Splenectomy and micro-vascular invasion were significant independent prognostic factors for disease-free survival.Gender,tumor number,and recurrence were independent prognostic factors for overall survival.CONCLUSION:Synchronous hepatectomy and hepatectomy potentially improves disease-free survival rates and alleviates hypersplenism without increasing the surgical risks for patients with HCC and hypersplenism.     

Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension

Phosphatidylinositol 3-kinase (PI3K) plays a central role in the metabolic actions of insulin. One 85 kDa regulatory subunit of PIK3 is encoded by phosphoinositide-3-kinase, the regulatory subunit 1 (PIK3R1). Our previous study has demonstrated that PIK3R1 was up-regulated significantly in the splenic macrophage (MΦ) of portal hypertensive spleen. In the present study, RNA interference specific to PIK3R1 was employed to investigate its inhibitive effects on the activity of MΦ associated with hypersplenism due to portal hypertension (HS-PHT).     

部分脾动脉栓塞术并发症研究进展

脾功能亢进（脾亢）发生于各种原因的脾淤血,是一种常见病,部分脾栓塞术（partial splenic embolization,PSE）是治疗脾亢的首选方法,随着该项技术的的广泛应用,其术后并发症也越来越受到重视。本文对PSE术后并发症的发病机理、与脾动脉栓塞程度的关系及并发症的处理作一综述,希望能够为PSE临床工作中尽早发现并正确处理并发症提供帮助。     

Acute cytomegalovirus infection in liver transplant recipients: An independent risk for venous thromboembolism

Acute cytomegalovirus (CMV) infection is a commonly encountered complication in the post liver transplant setting. We present a case of a 71-year-old male with acute CMV infection, initially presenting with a gastrointestinal bleed due to acute CMV gastritis and later on complicated by acute venous thromboembolism occurring as an unprovoked event in the post liver transplant period. Traditional risk factors for venous thromboembolism have been well described in the medical literature. Sporadic cases of thromboembolism due to CMV infection in the immune compromised patients have been described, especially in the post kidney transplant patients. Liver transplant recipients are equally prone to CMV infection particularly in the first year after successful transplantation. Venous thromboembolism in this special population is particularly challenging due to the fact that these patients may have persistent thrombocytopenia and anticoagulation may be a challenge for the treating physician. Since liver transplantation is severely and universally limited by the availability of donor organs, we feel that this case report will provide valuable knowledge in the day to day management of these patients, whose clinical needs are complex and require a multidisciplinary approach in their care and management. Evidence and pathophysiology linking both the conditions is presented along with a brief discussion on the management, common scenarios encountered and potential impact in this special group of patients.     

部分脾栓塞术治疗脾功能亢进36例临床分析

目的 讨论部分脾栓塞术（partial splenic embolization,PSE）治疗脾功能亢进的栓塞程度与临床疗效及并发症的关系.方法 对36例脾功能亢进患者行PSE治疗,观察术后并发症及术后3天、7天、1个月、3个月外周血白细胞、红细胞、血小板变化与栓塞程度的关系.结果 成功实施手术的36例患者术后均有不同程度的并发症,术后外周血WBC,RBC,PLT均有不同程度的升高,术前与术后1个月数值比较均有统计学意义（WBCt =2.751,P＜0.05,RBCt=1.960,P＜0.05,PLTt =3.435,P＜0.05）.并发症的程度、血细胞的改善程度与栓塞程度呈正相关.结论 PSE是治疗脾功能亢进安全、有效的方法,栓塞程度与临床疗效及并发症均呈正相关.     

部分脾栓塞术在原发性肝癌治疗中的应用研究

原发性肝癌常伴有脾功能亢进,传统的治疗脾亢的方式是脾切除。随着介入放射学的发展,脾部分栓塞术（ Partial splenic embolization ,PSE）在临床上应用的越来越广泛。肝癌伴脾功能亢进患者通过PSE可明显改善外周血象,降低门脉高压并发症。 PSE联合其他治疗可延长肝癌患者的生存期。现就PSE在肝癌治疗中的临床应用研究做一综述。     

部分性脾动脉栓塞联合内镜下套扎治疗肝硬化食管静脉曲张破裂出血的临床分析

目的探讨部分性脾动脉栓塞术联合经内镜套扎术治疗肝硬化脾功能亢进食管静脉曲张破裂出血的临床价值。方法对30例肝硬化门脉高压脾功能亢进的患者,胃镜下行曲张静脉套扎术,术后行部分性脾动脉栓塞术,术后观察近期止血效果和远期再出血发生率及外周血细胞等变化。结果部分性脾动脉栓塞术联合内镜套扎术近期止血效果显著(100%),食管-胃底曲张静脉消失率达83.3%;无手术死亡病例,无严重并发症,远期出血率为6.7%。外周血细胞及血小板均较术前明显回升。结论部分性脾动脉栓塞术联合内镜套扎术治疗肝硬化脾功能亢进食管静脉曲张破裂出血具有简便、安全、有效、创伤小、并发症少等优点,值得在临床推广应用。     

部分脾栓塞术的临床应用

目的：探讨部分脾栓塞术（PSE）的临床应用。方法：采用PSE治疗肝癌伴脾亢（HCC－HS）86例,其它继发性脾亢（SHS）26例,原发性血小板减少性紫癜（ITP）5例,其中20例行2次以上PSE。结果：平均栓范围HCC－HS组为36％,SHS组为60％,ITP组为74％,临床有效率分别为84．8％、88．5％、100％。HCC－HS组因单次栓塞范围较小,约20．9％（18／86）病人需行再次栓塞。全部病例均未发生严重并发症。结论PSE是安全有效,可作为外科脾切除的替代疗法,HCC－HS组为了减轻术后并发症PSE可分次进行。